Literature DB >> 15115474

Loss to follow-up of patients with malignant lymphoma.

S Brown1, A Belgaumi, D Ajarim, A Kofide, R Al-Saad, R Sabbah, A Ezzat, M Shoukri, R Barr, A Levin.   

Abstract

Loss to follow-up (LTFU) in cancer patients is a serious problem, yet there is little data on this and on the underlying reasons. Of 144 paediatric and 431 adult patients with lymphoma diagnosed in 1997/1998 at King Faisal Specialist Hospital and Research Center, Riyadh (KFSHRC), 30% and 48.5%, respectively, were LTFU after 4 years (excluding patients known to have died). In 2001-2002, 196 paediatric and adult lymphoma patients at KFSHRC were enrolled in a prospective study in which explanations were obtained in detail for non-attendance at follow-up appointments (No Show). Sixteen months after commencement of the study, 49 patients were No Show, because of patient-based communication problems (20), transportation problems (8), patient not contactable (18), and personal reasons (3). In addition, patients were recorded incorrectly as No Show through hospital/patient communication problems. The No Show patients, especially the 23 who failed to keep a second appointment, are identifiable as potential LTFU during the 3 years in which this cohort will be followed. This study and, we suggest, other studies on LTFU should stimulate interest in this issue, in the predisposing factors, and in strategies to address them.

Entities:  

Mesh:

Year:  2004        PMID: 15115474     DOI: 10.1111/j.1365-2354.2004.00461.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  2 in total

1.  The challenges of treating laryngeal carcinoma in jos, Nigeria.

Authors:  As Adoga; En Ma'an
Journal:  J West Afr Coll Surg       Date:  2011-04

2.  Intracranial tumors in children: a 10-year review from a single tertiary health-care center.

Authors:  Quratulain Riaz; Ehsun Naeem; Zehra Fadoo; Mahadev Lohano; Naureen Mushtaq
Journal:  Childs Nerv Syst       Date:  2019-07-02       Impact factor: 1.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.